Rapport Therapeutics Inc Dossier
Qualitative Analysis
Business overview
Rapport Therapeutics, Inc. (NASDAQ: RAPP) is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients suffering from central nervous system (CNS) disorders. The company leverages its proprietary Receptor Associated Proteins (RAP) technology platform to achieve neuroanatomical specificity, targeting discrete brain regions to minimize off-target side effects associated with traditional neuroscience medications. Its lead clinical candidate, RAP-219, is a TARP̃8-specific AMPA receptor negative allosteric modulator being developed for drug-resistant focal onset seizures (FOS), primary generalized tonic-clonic seizures (PGTCS), and bipolar mania.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Advancing the lead candidate RAP-219, a TARP̘8-specific AMPA receptor negative allosteric modulator, into Phase 3 clinical trials for focal onset seizures following positive Phase 2a results.
Expected impact: Establish clinical efficacy and safety to support regulatory approval for a potential first-in-class epilepsy treatment.
Expanding the clinical pipeline beyond epilepsy by developing RAP-219 for bipolar mania and advancing discovery-stage nicotinic acetylcholine receptor (nAChR) programs, including RAP-641 for chronic pain and migraine.
Expected impact: Validate the RAP technology platform across multiple neurological and psychiatric indications, diversifying clinical risk.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Expands the global reach of RAP-219 and accelerates global development efforts by adding Phase 3 clinical trial sites in Greater China under Tenacia's leadership.
Terms: Rapport received an upfront cash payment of $20 million and is eligible to receive up to $308 million in potential development and commercial milestones, plus tiered royalties ranging from mid-single digits to mid-teens on net sales in Greater China.